Navigation Links
Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
Date:5/17/2011

ional product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the timing and substance of our response to the FDA's requests from the QNEXA End of Review meeting; our response to, and continued dialogue with, the FDA relating to matters raised in the FDA's CRL for QNEXA; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the FDA's interpretation of and agreement with the information VIVUS submitted and may submit relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study, or OB-305; the FDA's requests, if any, to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; the review and questions from the EMA and CHMP on the MAA; substantial competition; the impact on future sales based o
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... LAKE CITY , Sept. 1, 2015 /PRNewswire/ ... that it will present at the First Annual ... in New York City.  Kelvyn H. Cullimore, ... present to leading institutional investment representatives on Tuesday, ... The Ladenburg Thalmann Conference will showcase leading-edge ...
(Date:9/1/2015)... VEGAS , Sept. 1, 2015  Dr. ... DigiPath Labs , the cannabis testing subsidiary of DigiPath, ... Patients Group about the lack of consistency in ... the online resource for medical cannabis information, she explained ... patients because their lack of uniform requirements makes standardization ...
(Date:9/1/2015)... , Sept. 1, 2015  Edwards Lifesciences Corporation ... science of heart valves and hemodynamic monitoring, is scheduled ... Conference at the Hyatt Regency Boston in ... Michael A. Mussallem , Edwards Lifesciences, ... speaker followed by a company discussion with conference attendees ...
Breaking Medicine Technology:DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3
... /PRNewswire/ -- Ethicon Endo-Surgery, Inc. today ... Digestive Disease Week (DDW) demonstrate the company,s novel, ... surgery (NOTES) procedures without laparoscopic support in porcine ... a new adaptable minimally-invasive surgical platform for NOTES ...
... Treatment Prediction Tool Wins Top Honors in Computerworld Honors Program ... IBM ) today announced it was selected for its contributions ... Computerworld Honors Program Laureate for 2009. , ... , , Developed by IBM researchers in Haifa, Israel, the ...
Cached Medicine Technology:Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Company's Toolbox 2Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Company's Toolbox 3Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Company's Toolbox 4IBM and EU Partners Create a Better Way to Fight AIDS Virus 2IBM and EU Partners Create a Better Way to Fight AIDS Virus 3IBM and EU Partners Create a Better Way to Fight AIDS Virus 4
(Date:9/1/2015)... , ... September 01, 2015 , ... Horizon Blue Cross ... 50 Best Companies for Latinas in the LATINA Style 50 Report that recognizes companies ... , For 2015, Horizon BCBSNJ climbs from number 24 to 21 of ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... and prevent different malignancies. Some options for cancer treatment are available belonging ... which distinctive approach is necessary for effective treatment. Several molecules have been ...
(Date:9/1/2015)... Minnesota (PRWEB) , ... September 01, 2015 , ... ... health care delivery options, Blue Cross and Blue Shield of Minnesota (Blue Cross) ... in 2016. , Based in San Francisco, Doctor On Demand provides immediate ...
(Date:9/1/2015)... ... 2015 , ... Negative pressure wound therapy (NPWT) entails the ... exudates, fluid, and infectious materials to prepare the wound for healing and closure. ... canisters, etc.) is projected to expand continuously through 2021. , Rising patient and ...
(Date:9/1/2015)... Houston, TX (PRWEB) , ... September 01, 2015 ... ... announce that it is now offering the MonaLisa Touch® , an innovative ... , The MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3
... ... Testing now provides super-private STD testing. The company tests for all types of STD,s, ... , ... 2009 -- Same Day STD Testing found on the web at: http://www.samedaystdtesting.com ...
... , American College of Medical Genetics (ACMG) Encourages ... History Day, Thanksgiving 2009 , BETHESDA, Md., Nov. 23 ... Day, as declared by the U.S. Surgeon General. The American ... family medical history and if they haven,t already gathered this ...
... Use of PA Preferred Products in Holiday Meals , HARRISBURG, ... a safe Thanksgiving meal this year, acting Agriculture Secretary Russell ... safety steps when preparing dinner and handling leftovers. , ... a critical step in making sure your Thanksgiving dinner is ...
... , Clinics Continue to Target Individuals in ... The Department of Health announced today they ... Health Centers in Delaware, Lancaster, and Lehigh counties on Tuesday, ... be administered for free to individuals in the recommended target ...
... appears to cause oxidative DNA damage and to increase ... November 23 in the Journal of the National ... to detoxify inorganic arsenic, it is now thought to ... To assess the role of arsenic biomethylation in ...
... Low-income children who don,t access health care from the same ... likely to have unmet health care needs compared with those ... Pediatrics . Studies like this are crucial ... for children, the researchers report. "In the current ...
Cached Medicine News:Health News:100% Anonymous, Confidential and Quick STD Screening Now Available with Same Day STD Testing 2Health News:'Family Health History and Genetics Privacy' is the Newest Addition to the ACMG Genetics & Your Health Video Series 2Health News:Pennsylvania Agriculture Department Encourages Proper Food Handling, Offers Safety Tips for Thanksgiving 2Health News:Pennsylvania Department of Health Announces Additional H1N1 Vaccination Clinics in Delaware, Lancaster, Lehigh Counties 2Health News:Children who lack continuity with a regular health care provider miss needed services 2Health News:Children who lack continuity with a regular health care provider miss needed services 3
...
No. 1. 30 mm conventional blades. Thin well-rounded tips....
Open blade speculum designed for both temporal and superior approach ocular surgery. Thumb screw adjusting mechanism. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Medicine Products: